W. Winn Chatham - Concepedia

Author

W. Winn Chatham

University of Alabama at Birmingham ORCID

Also Known As

W W Chatham, W Winn Chatham, W. Chatham, W. Winn Chatham, W. Winn. Chatham, W.W. Chatham, W.Winn Chatham, WALTER W. CHATHAM, Walter Chatham, Walter W Chatham

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

University of Alabama at Birmingham Birmingham VA Medical Center Feinstein Institute for Medical Research Medical University of South Carolina University of Alabama at Birmingham Hospital

About

W. Winn Chatham is an author at University of Alabama at Birmingham specializing in medicine, immunology, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.7K
2	Natural Sciences	2	2	45
3	Engineering	1	1	11
4	Health Sciences	1	1	1.5K
5	Public Health	1	1	78

W. Winn Chatham

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis Kenneth G. Saag, Gim Gee Teng, Nivedita M. Patkar, Arthritis Care & Research Orthopedic Physical TherapyPharmacotherapyInflammatory ArthritisRheumatoid DisorderChronic Disease Management	2008	1.5K
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome Bita Shakoory, Joseph A. Carcillo, W. Winn Chatham, Critical Care Medicine	2015	815
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis Yemil Atisha‐Fregoso, Susan Malkiel, Kristina M. Harris, Arthritis & Rheumatology	2020	197
Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D<sub>3</sub> on the Interferon Signature in Patients With Systemic Lupus Erythematosus Cynthia Aranow, Diane L. Kamen, Maria Dall’Era, Arthritis & Rheumatology	2015	86
Clinically significant valvular heart disease in systemic lupus erythematosus Karin V. Straaton, W. Winn Chatham, William J. Koopman, The American Journal of Medicine RheumatologyCardiovascular DiseaseSystemic Lupus ErythematosusSystemic Lupus Erythematosus TreatmentLupus	1988	78
Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements Chaim Putterman, Richard Furie, Rosalind Ramsey‐Goldman, Lupus Science & Medicine	2014	76
Immune Function in Patients with Rheumatoid Arthritis Treated with Etanercept Larry W. Moreland, R. Pat Bucy, Michael E. Weinblatt, Clinical Immunology InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseRheumatic Diseases	2002	70
Progressive joint destruction in a human immunodeficiency virus‐infected patient with rheumatoid arthritis Ulf Müller‐Ladner, Jörg Kriegsmann, Renate E. Gay, Arthritis & Rheumatism	1995	41
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study Cynthia Aranow, Cornelia F Allaart, Zahir Amoura, Annals of the Rheumatic Diseases	2024	40
Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase Warren D. Blackburn, Louis W. Heck, Leland D. Loose, Arthritis & Rheumatism	1991	39

Page 1